Current Report Filing (8-k)
March 21 2018 - 4:07PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported):
March 21, 2018
ADVAXIS,
INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
|
001-36138
|
|
02-0563870
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
305
College Road East
Princeton,
New Jersey, 08540
(Address
of Principal Executive Offices)
(609)
452-9813
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act.
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act.
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange Act.
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.[ ]
Item
5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On
March 21, 2018, at the 2018 annual meeting (the “Annual Meeting”) of stockholders of Advaxis, Inc. (the “Company”
or “Advaxis”), the stockholders approved an increase of authorized shares of common stock by 30,000,000 from the previously-authorized
65,000,000, bringing the total number of authorized shares of common stock to 95,000,000 shares (the “Amendment”).
This
Amendment is described in the Company’s proxy statement and annual report to stockholders for the year ended October 31,
2017, filed with the Securities and Exchange Commission on February 6, 2018 (the “Proxy Statement”). This description
of the Amendment is qualified in its entirety by reference to the text of the Amendment to the Company’s Amended and Restated
Certificate of Incorporation, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The Amendment became effective upon filing of the Amendment to the Company’s Amended and Restated Certificate of Incorporation
with the Secretary of State of the State of Delaware on March 21, 2018.
Item
5.07. Submission of Matters to a Vote of Security Holders.
The
following matters were voted on by the stockholders at the Annual Meeting: the election of directors, the approval of an amendment
to the Company’s Amended and Restated Certificate of Incorporation to increase the Company’s authorized share capital
by 30,000,000 shares of common stock, the approval of the Company’s 2018 Employee Stock Purchase Plan, and the ratification
of the appointment of Marcum LLP as Advaxis’ independent registered public accounting firm for the fiscal year ending October
31, 2018. At the meeting, Dr. David Sidransky, Dr. James P. Patton, Roni A. Appel, Richard J. Berman, and Dr. Samir N. Khleif
were re-elected to the Board.
Proposal
1
The
vote with respect to each nominee is set forth below:
Nominee
|
|
Total Votes For
|
|
|
Total Votes Withheld
|
|
|
Broker Non-Votes
|
|
Dr. David Sidransky
|
|
|
11,947,489
|
|
|
|
4,707,635
|
|
|
|
16,866,459
|
|
Dr. James P. Patton
|
|
|
11,460,967
|
|
|
|
5,194,157
|
|
|
|
16,866,459
|
|
Roni A. Appel
|
|
|
12,706,506
|
|
|
|
3,948,618
|
|
|
|
16,866,459
|
|
Richard J. Berman
|
|
|
12,825,177
|
|
|
|
3,829,947
|
|
|
|
16,866,459
|
|
Dr. Samir Khleif
|
|
|
12,269,918
|
|
|
|
4,385,206
|
|
|
|
16,866,459
|
|
Proposal
2
The
vote with respect to the approval of an amendment to Advaxis’ Amended and Restated Certificate of Incorporation is set forth
below:
Total Votes For
|
|
|
Total Votes Against
|
|
|
Abstentions
|
|
|
Broker Non-Votes
|
|
|
25,040,407
|
|
|
|
8,140,730
|
|
|
|
340,446
|
|
|
|
0
|
|
Proposal
3
The
vote with respect to the approval of Advaxis’ 2018 Employee Stock Purchase Plan is set forth below:
Total Votes For
|
|
|
Total Votes Against
|
|
|
Abstentions
|
|
|
Broker Non-Votes
|
|
|
13,161,780
|
|
|
|
3,384,560
|
|
|
|
108,784
|
|
|
|
16,866,459
|
|
Proposal
4
The
vote with respect to the ratification of the appointment of Marcum LLP as Advaxis’ independent registered public accounting
firm for the fiscal year ending October 31, 2018, is set forth below:
Total Votes For
|
|
|
Total Votes Against
|
|
|
Abstentions
|
|
|
Broker Non-Votes
|
|
|
29,615,336
|
|
|
|
3,156,631
|
|
|
|
749,616
|
|
|
|
0
|
|
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
The
following exhibits are furnished as part of this report:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ADVAXIS,
INC.
|
|
(Registrant)
|
|
|
|
|
By
|
/s/
Sara M. Bonstein
|
|
|
Sara
M. Bonstein
|
|
|
Executive
Vice President and Chief Financial Officer
|
Date:
March 21, 2018
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Sep 2023 to Sep 2024